|AHFS/Drugs.com||Multum Consumer Information|
|US NLM||Methyl aminolevulinate|
|Chemical and physical data|
|Molar mass||145.158 g·mol−1|
|3D model (JSmol)|
Metvix cream is applied topically and some time later the skin is illuminated with a proprietary red light (630 nm) source (medical lamp 'Aktilite') to activate the photosensitiser.
Approvals and indications
It has been reported as controversial in some quarters, with severe pain allegedly being experienced by some patients. 
Interim result of phototherapy for actinic keratosis with Metvix one week after exposure. Patient has light skin and blue eyes.
- "Photocure Divests Metvix to Galderma for EUR 51 Million". Archived from the original on 2011-02-07. Retrieved 2010-09-10.
- Ngan V (2003). "Methyl aminolevulinate photodynamic therapy (MAL PDT)". DermNet NZ. Archived from the original on 2016-06-28. Retrieved 2021-06-28.
- "New 5 Year Metvix-PDT Data Demonstrate Long-Term Efficacy & Reliability For NM Skin Cancer Treatment". EurekAlert!. 2006. Archived from the original on 2021-08-28. Retrieved 2021-06-28.
- O'Connor AE, Gallagher WM, Byrne AT (2009). "Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy". Photochemistry and Photobiology. 85 (5): 1053–74. doi:10.1111/j.1751-1097.2009.00585.x. PMID 19682322. S2CID 205950773.
- "Concerns raised over ALA skin cancer cream as patients recount 'horrendous' pain". Australian Broadcasting Corporation. 16 November 2013. Archived from the original on 2018-09-22. Retrieved 2021-06-28.